Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark S Sulkowski

Showing results (71-80 of 206) with videos related to

Pageof 21
Sort By:
The American Journal of Gastroenterology|August 8, 2008
Efficacy and safety of peginterferon alfa-2a/ribavirin in methadone maintenance patients: randomized comparison of direct observed therapy and self-administrationHerbert L Bonkovsky, Alan D Tice, Rockford G Yapp, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|March 17, 2004
Daily versus thrice-weekly interferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected persons: a multicenter randomized controlled trialMark S Sulkowski, Franco Felizarta, Cheryl Smith, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|June 13, 2006
Cost-effectiveness of peginterferon alfa-2a (40kDa) plus ribavirin in patients with HIV and hepatitis C virus co-infectionJohn Hornberger, Francesca J Torriani, Douglas T Dieterich, et al.
Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society|August 6, 2017
Utilization of hepatitis C virus RNA-positive donor liver for transplant to hepatitis C virus RNA-negative recipientBehnam Saberi, James P Hamilton, Christine M Durand, et al.
AIDS Patient Care and Stds|May 10, 2016
Interaction Between Alcohol Consumption Patterns, Antiretroviral Therapy Type, and Liver Fibrosis in Persons Living with HIVUsama Bilal, Bryan Lau, Mariana Lazo, et al.
Open Forum Infectious Diseases|May 9, 2017
Barriers to Hepatitis C Virus (HCV) Treatment Initiation in Patients With Human Immunodeficiency Virus/HCV Coinfection: Lessons From the Interferon EraTanyaporn Wansom, Oluwaseun Falade-Nwulia, Catherine G Sutcliffe, et al.
The Journal of Clinical Investigation|July 7, 2022
Integrated hepatitis B virus DNA maintains surface antigen production during antiviral treatmentTanner Grudda, Hyon S Hwang, Maraake Taddese, et al.
Hepatology (Baltimore, Md.)|October 31, 2002
Treatment of chronic hepatitis C: a systematic reviewGeetanjali Chander, Mark S Sulkowski, Mollie W Jenckes, et al.
Hepatology (Baltimore, Md.)|December 25, 2004
The effect of antiretroviral therapy on liver disease among adults with HIV and hepatitis C coinfectionShruti H Mehta, David L Thomas, Michael Torbenson, et al.
The Journal of Infectious Diseases|December 10, 2024
Direct-Acting Antivirals Quickly Eradicate Hepatitis C Virus From the Liver in People With Human Immunodeficiency Virus but Do Not Fully Reverse Immune ActivationJaiprasath Sachithanandham, Julia Leep-Lazar, Jeffrey Quinn, et al.
Pageof 21

Showing results (71-80 of 206) with videos related to

Sort By:
Pageof 21
The American Journal of Gastroenterology|August 8, 2008
Efficacy and safety of peginterferon alfa-2a/ribavirin in methadone maintenance patients: randomized comparison of direct observed therapy and self-administrationHerbert L Bonkovsky, Alan D Tice, Rockford G Yapp, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|March 17, 2004
Daily versus thrice-weekly interferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected persons: a multicenter randomized controlled trialMark S Sulkowski, Franco Felizarta, Cheryl Smith, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|June 13, 2006
Cost-effectiveness of peginterferon alfa-2a (40kDa) plus ribavirin in patients with HIV and hepatitis C virus co-infectionJohn Hornberger, Francesca J Torriani, Douglas T Dieterich, et al.
Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society|August 6, 2017
Utilization of hepatitis C virus RNA-positive donor liver for transplant to hepatitis C virus RNA-negative recipientBehnam Saberi, James P Hamilton, Christine M Durand, et al.
AIDS Patient Care and Stds|May 10, 2016
Interaction Between Alcohol Consumption Patterns, Antiretroviral Therapy Type, and Liver Fibrosis in Persons Living with HIVUsama Bilal, Bryan Lau, Mariana Lazo, et al.
Open Forum Infectious Diseases|May 9, 2017
Barriers to Hepatitis C Virus (HCV) Treatment Initiation in Patients With Human Immunodeficiency Virus/HCV Coinfection: Lessons From the Interferon EraTanyaporn Wansom, Oluwaseun Falade-Nwulia, Catherine G Sutcliffe, et al.
The Journal of Clinical Investigation|July 7, 2022
Integrated hepatitis B virus DNA maintains surface antigen production during antiviral treatmentTanner Grudda, Hyon S Hwang, Maraake Taddese, et al.
Hepatology (Baltimore, Md.)|October 31, 2002
Treatment of chronic hepatitis C: a systematic reviewGeetanjali Chander, Mark S Sulkowski, Mollie W Jenckes, et al.
Hepatology (Baltimore, Md.)|December 25, 2004
The effect of antiretroviral therapy on liver disease among adults with HIV and hepatitis C coinfectionShruti H Mehta, David L Thomas, Michael Torbenson, et al.
The Journal of Infectious Diseases|December 10, 2024
Direct-Acting Antivirals Quickly Eradicate Hepatitis C Virus From the Liver in People With Human Immunodeficiency Virus but Do Not Fully Reverse Immune ActivationJaiprasath Sachithanandham, Julia Leep-Lazar, Jeffrey Quinn, et al.
Pageof 21